{
  "pmcid": "6618092",
  "sha256": "f04297d5931561fd3e3d68ac22e5cfa4d9890eeda801ee68627e144f542504b3",
  "timestamp_utc": "2025-11-10T00:02:33.532570+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 10.556049618320614,
    "reading_ease": 38.82481234096696,
    "word_count": 262
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A Randomised Controlled Trial Comparing Endovenous Laser Ablation and Radiofrequency Ablation for Great Saphenous Vein Incompetence"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "A single-centre, double-blind, three-arm, superiority randomised controlled trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "Adult patients with symptomatic great saphenous vein (GSV) incompetence were randomised"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to receive EVLA, dRFA, or iRFA"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to compare the efficacy of EVLA with direct RFA (dRFA) and indirect RFA (iRFA)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was GSV occlusion rate at 12 months."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using stratified block randomisation, and allocation was concealed."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Patients, clinicians, and outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 451 patients were randomised, with 450 receiving treatment"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Intention-to-treat analysis showed occlusion rates"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "occlusion rates of 75.0% (95% CI 68.0 to 82.0) for EVLA, 59.9% (52.1 to 67.7) for dRFA, and 81.3% (75.1 to 87.6) for iRFA."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were more frequent in the EVLA group, particularly pain."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NL27871.075.10."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 24,
    "max_score": 25
  }
}